Quick Answer
NOVAVAX INC reported Diluted EPS of $2.58 per share for fiscal year 2025.
NOVAVAX INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.58 | +309.8% |
| 2024 | -$1.23 | +77.3% |
| 2023 | -$5.41 | +35.7% |
| 2022 | -$8.42 | +64.1% |
| 2021 | -$23.44 | -222.4% |
| 2020 | -$7.27 | -31.9% |
| 2019 | -$5.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.25 | -64.5% | -301.6% |
| June 30, 2025 | $0.62 | -37.4% | -78.8% |
| March 31, 2025 | $2.93 | +379.0% | +485.5% |
| September 30, 2024 | -$0.76 | +39.7% | -176.8% |
| June 30, 2024 | $0.99 | +70.7% | +194.3% |
| March 31, 2024 | -$1.05 | +69.2% | +16.7% |
| September 30, 2023 | -$1.26 | +41.4% | -317.2% |
| June 30, 2023 | $0.58 | +108.9% | +117.0% |
- NOVAVAX INC showed an increase of +309.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, NOVAVAX INC’s diluted eps has grown by 146.8% (from $5.51 per share (loss) to $2.58 per share).
- The most recent figure is from NOVAVAX INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: